Dual Source Ion Mobility-Mass Spectrometer

双源离子淌度-质谱仪

• 批准号: 10431202
• 负责人: John M Koomen
• 金额: $ 116.76万
• 依托单位: H. LEE MOFFITT CANCER CTR & RES INST
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-05-01 至 2023-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10431202
• 关键词: Advanced Malignant Neoplasm; Cancer Center; Charge; Chemicals; Complement; Computer software; Core Facility; Crystallization; Data; Data Analyses; Development; Devices; Electrospray Ionization; Funding; Gases; Immune; Individual; Investments; Label; Lipids; Liquid substance; Mass Spectrum Analysis; Measurement; Molecular; Pathology; Peptides; Phase; Proteins; Proteome; Proteomics; Research; Resolution; Resources; Sampling; Source; Spatial Distribution; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Time; Tissues; Training; United States National Institutes of Health; Vendor; Visualization; biomarker discovery; experimental study; high throughput screening; improved; instrument; instrumentation; ion mobility; ion source; mass spectrometer; mass spectrometric imaging; metabolome; metabolomics; new technology; novel; programs; tandem mass spectrometry; tumor; tumor heterogeneity; tumor metabolism

Project Summary/Abstract: The Bruker timsTOF fleX includes a liquid chromatograph (LC), matrix assisted laser desorption ionization (MALDI-2) and electrospray ionization (ESI) sources, trapped ion mobility spectrometer (tims), and quadrupole- time-of-flight (QTOF) mass spectrometer combined into an instrument that can analyze metabolites, lipids, and proteins with high content or high throughput. Most importantly, the gap between these two experiments can be bridged easily when both are conducted on the same instrument; for example, metabolomics data can be effectively integrated with mass spectrometry imaging. To describe the individual components, the liquid chromatograph provides separation of analytes to increase depth of proteome and metabolome sampling. The two ion sources enable analysis of liquid samples (ESI) or arrays of samples co-crystallized with matrix (MALDI). The trapped ion mobility spectrometer (tims) provides data for collision cross section (CCS) calculations to further define each analyte as well as gas phase enrichment of molecules into packets with similar CCS-to-charge ratios for mass analysis. The QTOF provides mass spectrometry and tandem mass spectrometry with high resolution and accurate mass measurement. Vendor software provides support for data analysis in both metabolomics and proteomics as well as visualization and analysis of mass spectrometry imaging. The addition of this instrument to our Proteomics & Metabolomics Core (P&MC) complements our existing LC-MS resources, provides novel capability for ion mobility-mass spectrometry, replaces a MALDI instrument that was decommissioned last year, and enhances resources available for mass spectrometry imaging. As tumor heterogeneity, the tumor-immune interface, and spatial distribution of analytes in tumors now have increasing importance, existing analytical platforms must be modified to meet these needs and additional investments in instrumentation are needed. The Bruker timsTOF fleX complements existing LC-MS instruments and optimizes the value of investment in new technology by lowering sample input requirements, creating capability for spatial omics of tissues, supporting high throughput screening with MALDI-tims-MS, and ion mobility separation of isomeric lipids, metabolites, and post-translationally modified or chemically labeled peptides. Examples provided by Bruker have been confirmed by demonstration data from our own samples. This device also can be used to improve biomarker discovery and integrate molecular measurements with traditional pathology workflows. The placement in a core facility with highly trained staff and extensive institutional support will maximize both the availability to the user group and their benefit from access to the instrument. Together, these advantages are expected to significantly advance cancer metabolomics and proteomics applications at Moffitt Cancer Center to support existing and planned NIH/NCI-funded research and fuel the development of a Cancer Metabolism Program to develop strategies to target tumor vulnerabilities.

项目摘要/摘要： Bruker timsTOF fleX 包括液相色谱仪 (LC)、基质辅助激光解吸电离仪 (MALDI-2) 和电喷雾电离 (ESI) 源、俘获离子迁移谱仪 (tims) 和四极杆 飞行时间 (QTOF) 质谱仪组合成一台仪器，可以分析代谢物、脂质和 高含量或高通量的蛋白质。最重要的是，这两个实验之间的差距可以 当两者在同一台仪器上进行时，很容易桥接；例如，代谢组学数据可以是 与质谱成像有效集成。为了描述各个成分，液体 色谱仪可分离分析物，以增加蛋白质组和代谢组采样的深度。这 两个离子源可分析液体样品 (ESI) 或与基质共结晶的样品阵列 （马尔迪）。俘获离子淌度谱仪（tims）提供碰撞截面（CCS）数据 计算以进一步定义每种分析物以及将分子气相富集到包中 用于质量分析的类似 CCS 与电荷比率。 QTOF 提供质谱分析和串联质量分析 具有高分辨率和精确质量测量的光谱测定。供应商软件提供支持 代谢组学和蛋白质组学的数据分析以及质谱的可视化和分析 成像。该仪器添加到我们的蛋白质组学和代谢组学核心 (P&MC) 中，补充了我们的 现有的 LC-MS 资源，提供离子淌度质谱的新颖功能，取代 MALDI 去年退役的仪器，增加了可用于质谱分析的资源 成像。作为肿瘤异质性、肿瘤-免疫界面以及肿瘤中分析物的空间分布 现在变得越来越重要，必须修改现有的分析平台以满足这些需求 需要对仪器进行额外投资。布鲁克 timsTOF fleX 补充了现有的 LC-MS 通过降低样品输入要求来优化新技术的投资价值， 创建组织空间组学能力，支持使用 MALDI-tims-MS 进行高通量筛选，以及 异构脂质、代谢物和翻译后修饰或化学标记的离子淌度分离 肽。布鲁克提供的示例已通过我们自己样品的演示数据得到证实。 该设备还可用于改进生物标志物发现并将分子测量与 传统病理学工作流程。安置在拥有训练有素的员工和广泛的核心设施中 机构支持将最大限度地提高用户群体的可用性及其从获取信息中获得的利益 乐器。总之，这些优势预计将显着推进癌症代谢组学和 莫菲特癌症中心的蛋白质组学应用支持现有和计划中的 NIH/NCI 资助的研究和 推动癌症代谢计划的发展，以制定针对肿瘤脆弱性的策略。